MoonLake Immunotherapeutics CFO Sells Shares Under Prearranged Plan
On May 11, 2026, MoonLake Immunotherapeutics' Chief Financial Officer Matthias Bodenstedt sold 13,653 shares for $273,000 under a pre-established Rule 10b5-1 trading plan. The sale represented just 1.1% of his direct holdings and did not involve indirect or derivative securities.
Tickers: $MLTX
Topics: biotech cfo_sales clinical_stage_company